MassChallenge

Extracellular specializes in bioprocessing technologies designed to optimize cell-culture efficiency for a sustainable bio-economy. The company offers expertise in bioprocess development, scale-up, media development, and cell-line development, enabling clients in cultivated meat, plant-cell culture food, bio-cosmetics, and bio-supplements to create sustainable alternatives.

Embryoxite is a biotechnology company specializing in non-invasive diagnostic services for pre-implantation embryos in human-assisted reproduction. It operates a platform that combines artificial intelligence, metabolomics, embryo imaging, and clinical data to enhance embryo selection accuracy and improve patient outcomes for fertility clinics and reproductive specialists.

SCALE develops sustainable bio-based materials that enhance performance while reducing costs and significantly lowering emissions. Its natural-fiber composites serve as eco-friendly alternatives to traditional materials in industries such as sporting goods, automotive, and aerospace.

Nature’s Principles is a Dutch biotechnology company that develops innovative fermentation technology. It uses mixed culture fermentation, inspired by principles of nature, to produce lactic acid and poly-lactic acid (bioplastic) from low-value waste streams like sugar beet pulp and molasses. This process enables clients to replace oil-based chemicals while improving sustainability metrics.

BioMixing is a biotechnology company dedicated to enhancing bio-fermentation processes. It specializes in developing innovative agitation systems for bioreactors, leveraging fluid dynamics principles to minimize cell damage and optimize mixing within the vessel. This enables other organizations to improve the efficiency of their fermenters and bioreactors, thereby addressing various biotechnological challenges.

Cellorama multipurpose devices, reagents, and processes are patent-pending and protect cell structure and integrity during many procedures. User-friendly and cost-effective devices are designed to minimize stressful stages in the laboratory while saving time and vital resources.

Developer of cancer drugs designed to help treat solid tumors. The company focuses on treating cancer diseases using biomaterials, enabling healthcare professionals to improve survival rates, reduce adverse effects, and offer new hope to patients.

Trove Health is a company that offers a clinical trial recruitment platform designed to facilitate access to patient data for patients, healthcare providers, and life sciences organizations. The platform creates a diverse and consented database of prospective trial participants, enabling researchers to efficiently identify and recruit patients who meet specific enrollment criteria across various geographies and therapeutic areas. By doing so, Trove Health supports the advancement of medical research while empowering patients to manage their own health data, including the potential to monetize it and receive personalized treatment options.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

Stellate Therapeutics is a global biotechnology company specializing in the development of small molecules derived from human gut bacteria into personalized therapies for neurological diseases. The company's platform has generated a portfolio of new drug candidates, with capabilities spanning discovery, screening, production, and diagnostic development.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Nanoplex is a healthcare and life sciences company.

ZiO Health is a biotechnology company that develops pocket-sized devices featuring proprietary biosensor technology and machine learning algorithms. These devices enable real-time laboratory testing at the point-of-care, enhancing patient care by combining immediate results with individual patient profiles.

Skygenic is an innovative infrastructure and data analysis platform that accelerates biological research by lowering barriers for scientists. Developed in collaboration with Harvard Medical School and Boston Children's Hospital, Skygenic enables non-programming scientists to perform their own data analysis, offloading workload from bioinformaticians, allowing more research at lower cost and faster pace.

YouthBio Therapeutics specializes in developing tissue-specific gene therapies based on partial cellular reprogramming, aiming to restore youthful gene expression in targeted cells. Its initial focus is on rejuvenating the brain to treat diseases like Alzheimer's by promoting cellular renewal in neurons and other brain cell types.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. This technology enables Narval to create novel first-in-class immunotherapeutics for diseases previously challenging to treat using monoclonal antibodies. Their focus includes respiratory, eye, and autoimmune diseases, with delivery methods such as inhaled antibodies, eye drops, and transdermal patches. Narval leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Azul Bio specializes in marine ecosystem preservation and enhancement, focusing on coral reef restoration. They employ advanced biological analysis services to monitor and maintain aquatic environments, offering DNA-based biodiversity assessments, species genotyping, microbiome profiling, and disease detection. This data empowers marine researchers and industries to improve aquaculture practices and safeguard ocean ecosystems against climate change.

Azooka Labs specializes in the production of proprietary fluorophores for biotechnology applications. Their products include fluorescent dyes and tags for DNA, RNA, chromosomes, live cells, and molecular-grade sample collection mediums. The company aims to provide affordable and sustainable biotech consumables globally.

Anviron is a biotechnology company that develops small-molecule inhibitor therapies for aggressive and late-stage cancers. The company focuses on scientific research to halt or shrink tumor growth in cancers such as pancreatic, breast, gastric, and cervical cancers, aiming to provide healthcare professionals with potential new treatment options. It employs a team of scientists, doctors, and clinicians dedicated to advancing cancer therapies.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

BioBQ cultivates meat directly from animal cells, specializing in slaughter-free beef brisket and other BBQ meats. Its proprietary technology produces these products in weeks, reducing environmental impacts compared to conventional cattle farming.

MyoGene Bio is a biotechnology company focused on developing innovative therapies for muscle diseases, with an initial emphasis on gene-editing treatments for Duchenne muscular dystrophy. The company employs advanced technologies to address the underlying causes of this condition, aiming to significantly improve disease progression and outcomes for patients. By targeting the root of the disorder, MyoGene Bio seeks to provide clinicians and patients with effective solutions that have a meaningful impact on the management of devastating muscle disorders.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Selmod, based in Basel's life science hub, develops innovative antibiotics targeting multi-drug resistant infections. Its first-in-class drug candidates focus on high-revenue hospital patients where first-line treatments have failed due to resistance. With a disruptive approach featuring new dual modes of action, all candidates have shown success in animal infection studies. The company aims to capture a significant share of the estimated $9 billion total available market for its three lead assets.

Ronawk is a biotechnology company specializing in the development of T-Block technology that produces patient-specific biologics for the treatment of various diseases, including cancer, organ injuries, and burns. The company's proprietary method allows for the growth of primary stem cells in a three-dimensional environment, preserving the essential characteristics of these cells outside the human body. This innovative approach enables the rapid expansion of stem cells, facilitating their use in early-stage diagnostics and the repair of damaged tissues. Ronawk's technology not only enhances the efficiency of growing human cells but also supports tissue generation and disease modeling, making significant contributions to the fields of regenerative medicine and reconstructive surgery.

LIALT Laboratorio de Investigación Alternativa develops toxicological evaluations without the use of animals. LIALT replaces the use of animals through the use of three-dimensional tissues in conjunction with internationally recognized protocols that provide more specific information on the mechanisms of toxic action than that obtained in animals, offering a solution to the problem previously exposed.

Stemloop is a biosensor company dedicated to harnessing biological technology to meet global challenges in chemical sensing and detection. The company focuses on developing innovative, cell-free biosensing products that simplify and enhance the testing process for chemical and molecular analysis. By utilizing genetically encoded sensing mechanisms, Stemloop aims to provide accurate and scalable solutions that are both cost-effective and accessible. This approach allows medical professionals to obtain faster and more reliable test results, ultimately improving healthcare outcomes while addressing unmet needs in laboratory testing. Through its novel technology, Stemloop seeks to revolutionize the landscape of biosensing and contribute meaningfully to various sectors.

Leucine Rich Bio is India's pioneering genomics-based company focused on microbiome analysis. It aims to bridge uncertainties in precision medicine by studying the 'second genome', offering personalized nutritional recommendations based on intestinal microflora, with applications across various health fields.

Michroma is a biotech company that develops natural, thermostable colorants for fungus-based food and cosmetics by leveraging fermentation of filamentous fungi and synthetic biology. It aims to replace synthetic pigments with natural pigments produced through biotechnological fermentation, delivering pH- and heat-stable colorants at scale for food and cosmetic applications. The company operates in multiple locations, including San Francisco, United States, and Rosario, Argentina, and pursues scalable production in bioreactors using proprietary fungal strains.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

Founded in Italy in 2016 by Silvia Scaglione and Maurizio Aiello, React4life is a biotech company dedicated to advancing biomedical research. The company specializes in the development of MIVO®, an innovative organ-on-a-chip technology that enhances the reliability and predictability of various applications such as pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals.

Matricelf is a biotechnology company focused on advancing tissue engineering and regenerative medicine. Founded in 2019 by Professor Tal Dvir from Tel Aviv University, the company specializes in the 3D printing of tissues and organs, utilizing a proprietary decellularization process that extracts stromal cells and extracellular matrix from small biopsy samples. This process generates a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells to create functional tissues through a patent-pending methodology. Matricelf is particularly dedicated to developing spinal cord implants for patients with traumatic injuries, aiming to restore neuronal activity and enhance motor functions, thereby improving patients' quality of life and facilitating their reintegration into the community.

EcoPhage develops and commercializes bacteriophage-based bactericides for agriculture. These natural solutions minimize environmental impact while maximizing efficacy against bacterial plant diseases, reducing global food losses. EcoPhage's proprietary platform, co-developed with the Weizmann Institute of Science, enables sustainable crop protection by harnessing the specificity and effectiveness of bacteriophages.

Biomineral Systems is a company focused on environmental biochemical research and technology aimed at addressing global environmental challenges. It offers a range of services, including phosphorus management, soil organic carbon management, and enhancement of soil quality. The company specializes in biogeochemical modeling for forest management, carbon trading and capture, as well as mineral synthesis and characterization. Additionally, Biomineral Systems provides consulting services and environmental policy advice to government agencies and medium to large enterprises. By equipping scientists and engineers with the tools and knowledge necessary to tackle issues related to food security, environmental sustainability, and biodiversity, Biomineral Systems plays a vital role in promoting ecological health and resilience.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

KriyaBio develops drug delivery technologies that enhance mucosal absorption of traditionally injected compounds. Its patented permeation enhancer KB01 facilitates this process, enabling pharmaceutical partners to reduce development costs and improve patient compliance.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Computational Life Inc. is a technology company based in Wilmington, Delaware, focused on developing advanced software for healthcare applications. Founded in 2018, the company specializes in creating a Digital Avatar Platform (DAP) that simulates human and animal physiological systems using validated mathematical models. Its software models various bodily functions, including arterial and venous dynamics, heart activity, microcirculation, pulmonary circulation, cerebrospinal fluid movement, and brain interstitial fluid behavior. The platform aims to enhance medical solutions by predicting personalized patient outcomes in multisystemic diseases, allowing healthcare providers to better manage complex conditions through informed simulations of medical treatments.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

BINK Bio is working on developing biotech alternatives to reduce environmental damage. The company focuses on and technologies in the fields of biotech based dyes.

Adiposs is a clinical-stage life science company developing innovative medical imaging products. Its flagship technology enables the early detection of cachexia, a debilitating body-wasting syndrome associated with cancer and other chronic diseases.

Vyasa Analytics is a technology company that specializes in providing an AI-powered platform tailored for life sciences and healthcare organizations. Its flagship product, Vyasa Layar, facilitates the integration and analysis of diverse data sources across both cloud and on-premise environments. This platform creates a unified data landscape that organizations can explore through a suite of low-code deep learning applications. Vyasa's offerings include advanced features such as dark data analytics, neural concept recognition, and secure cloud deployment, all designed to empower organizations to leverage deep learning for enhanced data insights. By enabling collaborative analytics and project-based deep learning, Vyasa Analytics supports its clients in effectively managing and utilizing their enterprise data.

Onexio Biosystems is a research and development company. They offer HTS screens that typically utilize a single reporter cell type that lacks important confounding biology, including drug metabolism and paracrine and endocrine cell interactions. Their microDUO supports co-culture and multi-culture to improve human relevance in drug discovery and chemical screening.

Amphasys develops and markets chip-based single-cell analysis technology, aiming to simplify, speed up, and miniaturize complex cell analyses for various applications. Founded in 2012 as a spin-off from Axetris AG, the company's technology enables label-free analysis of cell characteristics such as size, morphology, viability, and differentiation.

Onena Medicines is a biotechnology company developing innovative biological medicines. It focuses on addressing large unmet clinical needs for breast cancer and other serious orphan illnesses.

Convallo Bio is a biotechnology company focused on developing advanced beneficial bacteria aimed at enhancing the wellness of humans, animals, and the environment. By leveraging molecular technology, the company seeks to discover and deliver next-generation probiotics that can improve health outcomes. Convallo Bio's innovative approach positions it to address various wellness challenges through the production of effective microbial solutions.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals affected by skin diseases. Founded in 2019 and based in Chapel Hill, North Carolina, the company aims to enhance the health and well-being of pets by creating treatments for conditions such as atopic dermatitis and osteoarthritis. Aniluxx Biotechnology’s approach leverages a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects often associated with systemic medicines. Through its commitment to improving animal care, Aniluxx Biotechnology seeks to provide pet owners with effective solutions for managing their pets' health issues.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Mantle Biotech is a medical diagnostics company based in Cambridge, Massachusetts, founded in 2019. The company specializes in engineering heat-stable binding proteins that accurately identify disease biomarkers in patient samples. Through a process of directed evolution, Mantle Biotech modifies proteins derived from microbes to develop high-quality diagnostic reagents that are more stable and cost-effective than traditional options. Their innovative approach allows for the adaptation of these reagents to various diseases and testing formats, addressing significant challenges within the broader diagnostic industry. By focusing on unmet needs in global health, Mantle Biotech aims to provide clinics with robust and accurate alternatives to conventional diagnostic methods.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

InvivoSciences specializes in phenotypic compound screening services, focusing on first-in-class drug discovery and drug repositioning. The company's unique approach combines tissue engineering technology with assay automation and sample miniaturization to provide a rapid and cost-effective platform for therapeutic discovery.

MSL Pharma is a pharma company that performs ideation, analysis and identifies the solutions to treat diseases.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

Phylomics Diagnostics is a biotechnology company that specializes in the detection of multiple cancers.

KJ scientific ensures testing and analysis of chemicals product to safety for human and environmental health.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Fluent BioSciences is a life science technology company focused on single-cell molecular analysis, eliminating the need for complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), facilitates the instantaneous self-assembly of individual cells or molecules into millions of uniform partitions. This innovative approach allows for sensitive and unbiased preparation of proteins and nucleic acids, enhancing sequencing applications. By making single-cell and molecular analysis more accessible, Fluent BioSciences enables a broader range of researchers in biotechnology, pharmaceuticals, and academic institutions to conduct advanced analyses, thereby expanding market opportunities within the life sciences field.

Haima Therapeutics is a pre-clinical stage biotechnology company dedicated to developing bio-inspired therapies aimed at treating bleeding and other blood-related disorders. The company is focused on creating platelet-inspired therapeutics that address conditions where platelets are integral to disease progression, including thrombosis, inflammation, and cancer. Utilizing a novel, fully-synthetic nanoparticle-based hemostatic technology, Haima Therapeutics enhances the body's natural clotting mechanisms at the site of injury. This innovation is designed to help patients recover more rapidly from traumatic injuries, surgeries, and various blood-related ailments.

Clemedi AG is a Swiss-based company founded in 2018 that specializes in developing diagnostic workflows for infectious diseases. The company creates in vitro diagnostic tests by integrating next-generation sequencing and machine learning technologies. These innovative tests are designed to diagnose drug-resistant infections directly from patient samples within a single day, supporting timely and personalized antibiotic therapy. By providing healthcare professionals with critical information, Clemedi aims to enhance decision-making in the treatment of infectious diseases, ultimately contributing to the fight against antibiotic resistance. This approach is particularly significant given projections that antibiotic-resistant bacteria could lead to 10 million deaths annually by 2050.

Gateway Biotechnology is a biotechnology company focused on developing science-based solutions for hearing disorders. It specializes in creating animal model systems for preclinical trials of drug candidates, new drug development, and innovative drug delivery methods.

CrystalsFirst is a company providing structure-guided drug discovery technologies that leverage protein crystal data to accelerate screening and lead optimization. It develops methods to stabilize fragile protein crystals for screening and offers SmartSoak for small-molecule probes, SmartLib libraries for fragment-based discovery, and SmartRefine software for automated refinement of crystallographic data, together enabling high-confidence assessment of protein–ligand interactions. The company also creates atom-resolved 3D models that illustrate the geometry of protein–drug interactions. Its MAGNET platform integrates crystal-structure-first strategies with high-performance structural biology, large-scale computational modeling, generative AI and medicinal chemistry to identify novel molecules and druggable binding pockets for challenging targets. The platform supports rapid hit generation, scaffold diversification, and property optimization, aiding rational design from crystal structures and expanding chemical space. CrystalsFirst serves the biopharmaceutical sector, helping to tailor compounds for high affinity and uncover new modes of action across protein families and modalities. The company was founded in 2018 and is based in Marburg, Germany.

EQO specializes in environmental management using advanced molecular biology. It offers highly sensitive detection services for invasive species, along with an automated sampling platform for continuous monitoring. EQO also develops targeted biopesticides to eradicate invasives while minimizing off-target impacts.

NovoThelium is a biotechnology company founded in 2015 by biomedical engineers motivated by personal experiences with breast cancer. The company specializes in developing a tissue-engineered nipple matrix aimed at improving breast reconstruction for cancer survivors. NovoThelium's innovative approach involves a decellularization process that utilizes human donor breast tissue, which has been treated to remove DNA and donor cells while preserving essential proteins and structures. This process allows patients to regenerate a nipple using their own cells, resulting in a natural appearance with appropriate projection, pigmentation, and enhanced sensation. By focusing on nipple regeneration after mastectomy, NovoThelium addresses a significant need for more natural reconstructive options in breast cancer care.

BMSEED is a manufacturer of biomedical research tools focused on replicating stretch-induced neurotrauma in vitro to study injury mechanisms and evaluate therapies in academic and pharmaceutical settings. Its neurotrauma model enables direct comparison of electrophysiological activity between healthy and injured cells, aiding the assessment of neuroprotective treatments. The company also develops biomedical sustainable elastic electronic devices, including stretchable gold films and soft interfaces with cells, tissue, or skin, designed to recreate the cellular environment encountered in the human body. These tools aim to improve the predictive power of preclinical studies and reduce the rate of clinical trial failures by providing more accurate representations of how tissues respond to injury and treatment.

Scintia operates a biotechnology education platform that aims to simplify teaching, research, and innovation in synthetic biology. It provides interactive learning modules, hands-on laboratory equipment, and personalized teacher support to help students and educators in science, technology, engineering, arts, and mathematics explore biotechnology through practical experiences and develop critical thinking skills.

Simbiótica Labs specializes in developing biological technology solutions aimed at enhancing crop productivity. The company focuses on creating organic products that optimize nutrient absorption in plants while ensuring environmental sustainability. By revitalizing the root ecosystem and fostering synergy among microorganisms, Simbiótica Labs enables its clients to improve crop yields effectively. Its innovative approach seeks to balance agricultural productivity with ecological health, positioning the company as a leader in sustainable agricultural practices.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Cellular Preservation Technologies is a biotechnology company developing methods to preserve biological cells and tissues using hyperbaric xenon gas and refrigeration. Its preservation technology significantly improves platelet durability, increasing supply, reducing waste, and lowering the risk of bacterial infection, thereby helping hospitals and blood banks provide more efficient, timely, and effective critical therapeutic services to patients.

Founded in 2014, Neurescence Inc. specializes in developing innovative assessment tools for brain diseases. The company offers GRIN lenses for neural imaging and Quartet, a miniature fluorescence microscope optimized for neuronal calcium imaging.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

ReviveMed develops a precision-medicine platform that transforms untargeted metabolomic data into actionable insights. Its network-based machine learning algorithm integrates metabolomics with other molecular information, facilitating the development of therapeutics for liver diseases.

Halo Life Science is a company dedicated to enhancing human health and wellness through innovative nutritional solutions. After three years of research and development, the company has introduced Naturalin™, a patent-pending phytonutrient designed to improve the nutritional value of everyday foods and beverages. This multifunctional bioactive is also available in various nutritional supplement formats, making it suitable for addressing chronic conditions, illnesses, and obesity. Supported by research from the Dell Pediatric Research Institute at The University of Texas at Austin, Naturalin™ has been validated for safety and efficacy. Halo Life Science's mission is to provide safe, effective, and accessible food and nutritional products to consumers, ensuring that enhanced nutrition is available to everyone, everywhere.

Bezoar Laboratories is focused on enhancing the health of humans, animals, and the environment through innovative microbial solutions. The company develops probiotic medical and pharmaceutical products designed to alleviate gastrointestinal issues, particularly those related to methane gas production. Its offerings are formulated to be free of gluten and dairy, while maintaining low acidity levels. This formulation aims to provide customers with relief from symptoms such as bloating, constipation, and diarrhea. Bezoar Laboratories is committed to creating effective solutions that promote overall well-being.

Octagon Therapeutics is a preclinical-stage biopharmaceutical company developing targeted immunomodulator medicines for chronic autoimmune and inflammatory diseases. Incorporated in 2016, the company is based in Cambridge, Massachusetts.

MobioSense is engaged in the development of advanced diagnostic solutions for heart disease. The company's flagship product, HERO, is a portable, high-sensitivity troponin test that enables rapid diagnosis of heart attacks. Unlike conventional tests that require multiple samples over an extended period, HERO can provide results in just three hours, facilitating immediate decision-making in both hospital and ambulance settings. This innovation not only improves patient care by allowing for timely interventions but also helps alleviate emergency room congestion by directing patients to the appropriate care pathways. In addition to its heart disease monitoring capabilities, MobioSense is also involved in creating detection reagents for diseases such as African Swine Fever and COVID-19, further enhancing its commitment to healthcare advancements.

Day Zero Diagnostics develops sequencing-based diagnostics for infectious diseases. Its proprietary technologies enable rapid identification of bacterial species and antibiotic resistance profiles from clinical samples, targeting bloodstream infections and sepsis initially. The company aims to improve patient outcomes by providing comprehensive diagnoses within hours instead of days.

Reminisciences develops a symbiotic treatment and a companion diagnostic for Alzheimer's disease through targeting the gut microbiome. Reminisciences exploits the crucial role of gut microbiota in human physiology and more specifically as we have discovered in Alzheimer's disease. There is no effective treatment for Alzheimer, despite 51 million patients in need. Our company develops 2 products: CerebralX, a symbiotic therapeutic treatment to restore altered gut microbiota and stop or delay Alzheimer's disease, and ReminiTest, a diagnostic based upon microbiota profiling.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

NerveSolutions is a biomedical technology company specializing in the development of implantable nerve interface devices. Its flagship product is a surgical device designed to prevent neuroma formation after amputation or nerve injury, enabling surgeons to provide optimal treatment and helping patients regain function.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

General Biotechnologies identifies and develops undervalued discoveries in the life sciences. Their flagship program — Nivien Therapeutics — is a venture-backed oncology startup spun out of Harvard Medical School.

Structured Immunity is a protein engineering company focused on enhancing the safety and effectiveness of T cell receptor-based therapies. Founded in 2017 by David Hardwicke and Timothy Riley, the company leverages over 20 years of research from the laboratory of Brian Baker to develop advanced techniques for optimizing T cell receptors. By increasing the target specificity of these receptors, Structured Immunity aims to improve drug efficacy while minimizing potential side effects associated with T cell therapies. The company specializes in enhancing the human immune system for cell-based cancer immunotherapy, providing pharmaceutical firms with innovative solutions for engineering patentable cellular cancer therapies with improved tumor targeting capabilities.

GliaPharm is a Swiss biotechnology company focused on developing treatments for neurological and psychiatric disorders by targeting glial cells to support brain metabolism. It has developed the GliaX platform to identify drugs that modulate glial activity and energy metabolism. The platform combines high-throughput screening using enzymatic and primary-cell assays with metabolic characterization of compounds in vitro in primary brain cell cultures and in vivo in rodent brains. Research includes various rodent models of brain aging, Alzheimer's disease, and ALS, with selective contract research organizations handling parts of the drug-development process. Founded in 2016 and based in Geneva, GliaPharm pursues glia-mediated neuroprotection and maintenance of cognitive function.

Founded in 2013, Torigen Pharmaceuticals specializes in developing innovative cancer care solutions for pets. Based in Farmington, Connecticut, the company focuses on advancing scientific research to bring novel approaches to companion animal cancers.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Hive is a crowdsourcing platform for biomedical PhDs ​

Akanocure Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative anti-cancer therapies aimed at treating various forms of cancer, particularly those that have metastasized. Recognizing that metastasis is responsible for the majority of cancer-related deaths, Akanocure focuses on creating novel small molecules that can block metastatic processes. The company's approach emphasizes the synthesis and development of bio-targeted chemotherapeutic agents derived from natural resources, which not only target cancer cells more effectively but also address the side effects associated with conventional chemotherapy. By leveraging the expertise of its team throughout the drug discovery and development process, Akanocure aims to enhance treatment outcomes and improve the quality of life for cancer patients.

Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.

ReviveMed develops a precision-medicine platform that transforms untargeted metabolomic data into actionable insights. Its network-based machine learning algorithm integrates metabolomics with other molecular information, facilitating the development of therapeutics for liver diseases.

Octagon Therapeutics is a preclinical-stage biopharmaceutical company developing targeted immunomodulator medicines for chronic autoimmune and inflammatory diseases. Incorporated in 2016, the company is based in Cambridge, Massachusetts.

LYF Rescue Drone specializes in developing an innovative search and rescue system aimed at finding avalanche victims more efficiently than traditional methods. The company addresses the critical issue that approximately 150 ski freeriders die annually due to avalanches, with current technologies like avalanche victim detectors (AVDs) often being slow and user-dependent. LYF Rescue Drone's solution involves a portable drone system designed to autonomously locate buried victims by reducing human error and search time. This technology enhances the chances of survival for those caught in avalanches by quickly identifying their location and alerting rescue teams.

UrSure, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing and commercializing diagnostic tests that enhance medication adherence. Founded in 2015, UrSure specializes in patient-friendly urine and blood test kits designed to measure adherence to HIV medications, including pre-exposure prophylaxis (PrEP). By providing these diagnostic tools, UrSure aims to improve health outcomes for individuals undergoing treatment and prevention for HIV, thereby addressing a critical need in the management of the disease.

eggXYt is a biotechnology company focused on the early sex detection of chick embryos immediately after eggs are laid. The company has developed a non-invasive gene-editing technology that utilizes clustered regularly interspaced short palindromic repeats to add a genetic marker to the eggs. This marker causes male eggs to emit a glow when scanned, allowing poultry farms to identify and incubate only female eggs. By enabling early identification, eggXYt's technology helps to streamline operations, reducing waste associated with the incubation of male chicks, which are typically culled after identification. This innovative approach not only enhances efficiency in poultry production but also supports sustainability within the food industry.